

AD _____

Award Number: DAMD17-99-1-9512

TITLE: Tumor Targeting with Phage Library

PRINCIPAL INVESTIGATOR: Jih Tung Pai, M.D., Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, California 92037

REPORT DATE: July 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2000		3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 99 - 30 Jun 00)
4. TITLE AND SUBTITLE Tumor Targeting with Phage Library			5. FUNDING NUMBERS DAMD17-99-1-9512	
6. AUTHOR(S) Jih Tung Pai, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Burnham Institute La Jolla, California 92037 E-MAIL: pai@burnham-inst.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (<i>Maximum 200 Words</i>) <p>I have proposed to identify peptides that bind to the vasculature of prostate cancers by using a technique developed in our laboratory called "<i>in vivo</i> phage display", and then to use these peptides to isolate their vasculature-specific receptors. Specific markers for the vasculature of prostate cancers can be good targets for anti-prostate cancer drugs and will lead to a greater understanding of prostate carcinogenesis. I have also taken an alternative approach to identify prostate cancer vasculature-specific markers by directly comparing the mRNA profiles between endothelial cells from prostate tumors and normal organs.</p> <p>For this project I have accomplished the following:</p> <ul style="list-style-type: none"> ¥ Established an expression cloning strategy using phage-displayed RGD4C peptide and $\alpha v\beta 3$-expressing HEK cells as a model system. ¥ Established three ecdysone-inducible R-Ras cell lines for testing cDNA microarray and GeneChip technologies. ¥ Used sequential <i>in vitro</i> transcription to setup a highly sensitive gene-profile assay that is 10,000 times more sensitive than the original method. ¥ Isolated highly pure endothelial cell populations from various organs and prostate tumors of Tie-2/LacZ transgenic mice. 				
14. SUBJECT TERMS Prostate Cancer, Phage Targeting, GeneChip, cDNA Microarray			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N Where copyrighted material is quoted, permission has been obtained to use such material.

N Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Jh-tung Pai 7/27/00
PI - Signature Date

Table of Contents

Cover.....	1
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	7

Introduction:

I have proposed to identify peptides that bind to the vasculature of prostate cancers by using a technique developed in our laboratory called "*in vivo* phage display". These peptides would be able to home to prostate cancers when injected into the circulation.

I would then use these peptides to isolate their vasculature-specific receptors. These receptors could be specific markers for the vasculature of prostate cancers and lead to a greater understanding of what kinds of vascular surface proteins are up-regulated during prostate carcinogenesis. Both the resulting peptide ligands and receptors would enable us to develop more efficacious but less toxic anti-prostate cancer drugs.

Body:

I started to develop a expression cloning method that used phage-displayed RGD-4C peptide as a probe. The RGD4C peptide tightly binds to $\alpha v \beta 3$ integrin and is a tumor-targeting peptide. I transfected HEK293 cells with either $\alpha v \beta 3$ cDNAs or vector control and determined that phage-displayed RGD-4C peptide bound to the $\alpha v \beta 3$ transfected cells relative to cells transfected with vector alone. I also performed immunohistochemical staining with anti-phage antibody, and observed a distinct staining pattern only with the $\alpha v \beta 3$ transfected group. These data indicates the feasibility of using phage-displayed RGD-4C peptide as a probe to identify $\alpha v \beta 3$ -positive cells in a cDNA library expressed in HEK293 cells.

Concurrently, I performed *in vivo* phage display on xenograft tumors in nude mice. The screening process was more difficult and took longer than expected because of the variability in tumor size and composition, along with the time necessary to grow tumors of a proper size. So far, I have not obtained tumor-targeting phage that are suitable as probes in an expression cloning system.

I have initiated an alternative approach to identify receptors that are specifically expressed on the endothelial cells that comprise prostate cancer's vasculature. This approach involves isolating endothelial cells from prostate tumors and comparing their mRNA expression profile with endothelial cells from normal organs. The technology of cDNA microarrays and GeneChips have proven to be very useful in analyzing mRNA expression profiles. The sensitivity of the assays have been improved to a degree that it is feasible to do the assay with a small amount of endothelial cells, and I should be able to recover sufficient material from a few mouse prostate tumors.

This approach has several steps:

1. Establish inducible cell lines as source of mRNA.

To this end, I have established three inducible stable cell lines: pIND-R-Ras-CA, pIND-R-Ras-DN, and pIND-R-Ras-WT. Respectively, these three cell lines express constitutively active R-Ras, dominant-negative R-Ras, and wild type R-Ras under the control of the inducible ecdysone promoter. R-Ras was shown in our laboratory to increase cell adhesion. This inducible system is an ideal test for cDNA microarrays and GeneChips because we can directly compare the non-induced and induced states. The nature of the inducible system allows me to use R-Ras up-regulation as an internal positive control. I have identified several up-regulated and down-regulated genes upon induction of constitutively active R-Ras. One up-regulated and one down-regulated gene have been further verified by northern blot analysis.

2. Use sequential *in vitro* transcription to setup a high-sensitivity gene-profile assay.

It is essential to have a high-sensitivity assay for cDNA microarray and GeneChip analyses because one can only get a small amount of high purity endothelial cells from mouse tumors and organs. I have setup this assay in collaboration with Dr. William Wachsman, the director of UCSD's GeneChip facility. We have reduced the required starting material from 100 μ g to 10 ng of total RNA while essentially maintaining the same accuracy. This represents a 10,000-fold increase in the assay's sensitivity.

3. Isolate highly pure endothelial cells from various organs and prostate tumors of mice.

It is crucial that we can isolate a highly pure population of endothelial cells in order to get correct and useful expression profiles. I obtained Tie-2/LacZ transgenic mice from Jackson laboratory to make the isolation process and purity verification easier. Tie-2/LacZ transgenic mice express the β -galactosidase gene under the control of Tie-2's promoter. The Tie-2 promoter is only turned on in endothelial cells. I can easily isolate LacZ positive cells by using a fluor-producing substrate in combination with a cell sorting procedure. This procedure has been established for the spleens and lungs of Tie-2/LacZ transgenic mice. I am in the process of breeding Tie-2/LacZ mice with the TRAMP prostate cancer model mice, so I can obtain endothelial cells from prostate tumors.

List of key research accomplishments:

- ¥ Established an expression cloning strategy using phage-displayed RGD4C peptide and $\alpha v\beta 3$ -expressing HEK cells as a model system.
- ¥ Established three ecdysone-inducible R-Ras cell lines for testing cDNA microarray and GeneChip technologies.
- ¥ Used sequential *in vitro* transcription to setup a highly sensitive gene-profile assay that is 10,000 times more sensitive than the original method.
- ¥ Isolated highly pure endothelial cell populations from various organs and prostate tumors of Tie-2/LacZ transgenic mice